Logo

WaveSense nRichDx

Dec 02, 2016

WaveSense has launched the nRichDx system for bulk isolation of target cells and nucleic acids from liquid biopsies. The new system uses WaveSense's proprietary paramagnetic bead technology to capture circulating tumor cells and cell-free DNA or RNA in quantities sufficient for subsequent next-generation sequencing or PCR analysis. The system can capture cells and nucleic acids from an array of sample types including blood, urine, and bone marrow, and is specifically designed and optimized for high-volume, low-yield specimens, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.